Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03956680 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
A Phase 1 study of Advanced Solid Cancers, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 5
- Study locations
NCT03956680: Completed Phase 1 study of Advanced Solid Cancers, sponsored by Bristol-Myers Squibb.
NCT03956680 is a Phase 1 study of Advanced Solid Cancers that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 54 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03956680, a Phase 1 study of Advanced Solid Cancers, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, best route of administration, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab in participants with cancers that have failed to respond to T cell checkpoint inhibiting antibodies.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DRUG BMS-986301
Study Locations (5)
Illinois
- Local Institution - 0003 - Chicago
Missouri
- Local Institution - 0005 - St Louis
Pennsylvania
- Local Institution - 0006 - Pittsburgh
Tennessee
- Local Institution - 0002 - Nashville
Ontario
- Local Institution - 0001 - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2024-04-24 |
| Phase | Phase 1 |
What the finished NCT03956680 record still lists
NCT03956680 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Advanced Solid Cancers appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT03956680 lists 5 locations in 5 states (Illinois, Missouri, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT03956680 about?
NCT03956680 is a clinical study titled "An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers". The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, best route of administration, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab in participants with cancers ...
What is the current status of trial NCT03956680?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2019-03-26. Estimated completion is 2024-04-24.
What conditions does trial NCT03956680 study?
This clinical trial studies the following conditions: Advanced Solid Cancers.
What interventions are being tested in trial NCT03956680?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), BMS-986301 (DRUG).
Who is sponsoring clinical trial NCT03956680?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03956680 being conducted?
This trial has 5 study locations across Illinois, Missouri, Pennsylvania, Tennessee, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03956680's enrollment target sits among peer trials
54 931st of 2000 higher than 1,053 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI